Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06407635 · ClinicalTrials.gov registry record · Phase 1
A Study of Psilocybin for PTSD
A Phase 1 study of Post Traumatic Stress Disorder, sponsored by Johns Hopkins University.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06407635 is a Phase 1 study of Post Traumatic Stress Disorder that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 20 participants, below the 1,117-participant average among 144 other Post Traumatic Stress Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06407635, a Phase 1 study of Post Traumatic Stress Disorder, is active but no longer recruiting, sponsored by Johns Hopkins University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed open-label, controlled study at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) will test the following primary hypotheses in adult patients with chronic PTSD who are currently taking a serotonin reuptake inhibitor: psilocybin therapy will be feasible and safe for participants, significantly remediate PTSD symptoms, and enhance wellbeing and quality of life. In addition, the study will examine whether elements of evidence-based trauma-focused psychotherapy enhance treatment response when paired with psilocybin.
Conditions Studied
Interventions
- DRUG Psilocybin
- OTHER Trauma-focused psychotherapy
- OTHER Standard psychological support
Study Locations (1)
Maryland
- Johns Hopkins Center for Psychedelic and Consciousness Research - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-06-07 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06407635
The ClinicalTrials.gov registry entry for NCT06407635 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,117-participant average among 144 other Post Traumatic Stress Disorder trials with a reported enrollment target (98% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 3 interventions - of which Psilocybin is the first listed.
NCT06407635 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06407635 about?
NCT06407635 is a clinical study titled "A Study of Psilocybin for PTSD". The proposed open-label, controlled study at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) will test the following primary hypotheses in adult patients with chronic PTSD who are currently taking a serotonin reuptake inhibitor: psilocybin therapy will be feasible and safe...
What is the current status of trial NCT06407635?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-06-07. Estimated completion is 2027-05.
What conditions does trial NCT06407635 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder.
What interventions are being tested in trial NCT06407635?
The interventions under investigation include: Psilocybin (DRUG), Trauma-focused psychotherapy (OTHER), Standard psychological support (OTHER).
Who is sponsoring clinical trial NCT06407635?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06407635 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
RECRUITING · Phase 1
-
Biological Signatures, Probiotic Among Those With mTBI and PTSD
COMPLETED · Phase 1
-
Cannabidiol as a Treatment for AUD Comorbid With PTSD
COMPLETED · Phase 1
-
Virtual Reality (VR) Therapy for Post-Traumatic Stress Disorder (PTSD)
COMPLETED · Phase 1
-
Bringing What Works to Youth in Corrections: A Trauma Intervention
COMPLETED · Phase 1
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.